



NATCO PHARMA LIMITED

Statement of stand-alone Financial Results for the quarter and nine months ended 31st December 2015

Rs. in lakhs

PART I : STATEMENT OF STAND-ALONE FINANCIAL RESULTS	THREE MONTHS ENDED (UN-AUDITED)			YEAR-TO-DATE FIGURES FOR NINE MONTHS ENDED ON (UN-AUDITED)		YEAR ENDED (AUDITED)
	31 December 2015	30 September 2015	31 December 2014	31 December 2015	31 December 2014	31 March 2015
<b>01. INCOME FROM OPERATIONS</b>						
a) Net Sales/Income from Operations (Net of Excise Duty & Sales Tax)	23,402	18,991	15,577	61,010	49,888	66,450
b) Other Operating Income	1,124	1,213	1,119	3,125	4,084	5,107
<b>TOTAL INCOME FROM OPERATIONS</b>	<b>24,526</b>	<b>20,204</b>	<b>16,696</b>	<b>64,135</b>	<b>53,972</b>	<b>71,557</b>
<b>02. EXPENDITURE</b>						
a) Cost of materials consumed	7,912	6,376	4,881	20,469	12,593	17,858
b) Purchases of stock-in-trade	-	-	-	37	-	88
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(852)	(1,838)	(198)	(3,715)	1,004	(876)
d) Employee benefits expense	4,162	3,551	2,793	11,177	8,417	11,619
e) Depreciation and amortization expense	1,170	1,124	1,075	3,414	3,117	4,246
f) Other Expenses	6,788	6,037	4,432	17,518	15,026	20,010
<b>TOTAL EXPENSES</b>	<b>19,180</b>	<b>15,250</b>	<b>12,983</b>	<b>48,900</b>	<b>40,157</b>	<b>52,945</b>
<b>03. Profit/(Loss) from Operations before other income, finance costs and exceptional items</b>	<b>5,346</b>	<b>4,954</b>	<b>3,713</b>	<b>15,235</b>	<b>13,815</b>	<b>18,612</b>
04. Other Income	640	308	712	1,231	1,100	1,355
<b>05. Profit/(Loss) from ordinary activities before finance Cost and exceptional items</b>	<b>5,986</b>	<b>5,262</b>	<b>4,425</b>	<b>16,466</b>	<b>14,915</b>	<b>19,967</b>
06. Finance costs	332	754	811	1,863	2,146	3,013
<b>07. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items</b>	<b>5,654</b>	<b>4,508</b>	<b>3,614</b>	<b>14,603</b>	<b>12,769</b>	<b>16,954</b>
08. Exceptional Item	-	-	1,513	-	1,513	1,513
<b>09. Profit/(Loss) from ordinary activities before tax</b>	<b>5,654</b>	<b>4,508</b>	<b>2,101</b>	<b>14,603</b>	<b>11,256</b>	<b>15,441</b>
10a. Current Tax expense	1,206	962	425	3,116	2,357	3,252
10b. Deferred Tax expense /(reversal)	94	86	15	266	118	(3,103)
<b>11. Net Profit/(Loss) from ordinary activities after tax</b>	<b>4,354</b>	<b>3,460</b>	<b>1,661</b>	<b>11,221</b>	<b>8,781</b>	<b>15,292</b>
12. Extraordinary items (net of tax expenses)	-	-	-	-	-	-
<b>13. Net Profit/(Loss) for the period</b>	<b>4,354</b>	<b>3,460</b>	<b>1,661</b>	<b>11,221</b>	<b>8,781</b>	<b>15,292</b>
14. Paid-up Equity Share Capital	3,483	3,483	3,323	3,483	3,323	3,323
15. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	84,576
<b>16. Earnings per share</b> (each share of Rs.2/-face value)						
Basic EPS before and after extraordinary item (Rs.) - non-annualized	2.50	2.07	1.00	6.63	5.31	9.23
Diluted EPS before and after extraordinary item (Rs.) - non-annualized	2.49	2.07	1.00	6.62	5.31	9.23

Dated at Hyderabad, this, the 11th day of February, 2016.  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited

  
V.C. Nannapaneni  
Chairman & Managing Director



NATCO PHARMA LIMITED

Statement of consolidated Financial Results for the quarter and nine months ended 31st December 2015

Rs.in lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS

PARTICULARS	THREE MONTHS ENDED (UN-AUDITED)			YEAR-TO-DATE FIGURES FOR NINE MONTHS ENDED ON (UN-AUDITED)		YEAR ENDED (AUDITED)
	31 December 2015	30 September 2015	31 December 2014	31 December 2015	31 December 2014	31 March 2015
<b>01. INCOME FROM OPERATIONS</b>						
a) Net Sales/Income from Operations (Net of Excise Duty & Sales Tax)	26,312	22,277	18,427	70,158	58,363	77,420
b) Other Operating Income	1,292	1,213	1,119	3,307	4,084	5,107
<b>TOTAL INCOME FROM OPERATIONS</b>	<b>27,604</b>	<b>23,490</b>	<b>19,546</b>	<b>73,465</b>	<b>62,447</b>	<b>82,527</b>
<b>02. EXPENDITURE</b>						
a) Cost of materials consumed	7,649	6,240	6,503	19,633	18,282	16,726
b) Purchases of stock-in-trade	2,340	2,315	-	7,043	-	8,428
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(774)	(1,819)	(198)	(3,741)	1,004	(917)
d) Employee benefits expense	4,695	4,304	3,329	13,025	9,854	13,692
e) Depreciation and amortization expense	1,332	1,268	1,218	3,864	3,446	4,726
f) Other Expenses	7,567	6,601	5,156	19,783	16,916	23,261
<b>TOTAL EXPENSES</b>	<b>22,809</b>	<b>18,909</b>	<b>16,008</b>	<b>59,607</b>	<b>49,502</b>	<b>65,916</b>
<b>03. Profit/(Loss) from Operations before other income, finance costs and exceptional items</b>	<b>4,795</b>	<b>4,581</b>	<b>3,538</b>	<b>13,858</b>	<b>12,945</b>	<b>16,611</b>
04. Other Income	536	207	734	926	1,171	1,491
<b>05. Profit/(Loss) from ordinary activities before finance Cost and exceptional items</b>	<b>5,331</b>	<b>4,788</b>	<b>4,272</b>	<b>14,784</b>	<b>14,116</b>	<b>18,102</b>
06. Finance costs	358	766	851	1,932	2,231	3,168
<b>07. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items</b>	<b>4,973</b>	<b>4,022</b>	<b>3,421</b>	<b>12,852</b>	<b>11,885</b>	<b>14,934</b>
08. Exceptional Item	-	-	1,513	-	1,513	1,513
<b>09. Profit/(Loss) from ordinary activities before tax</b>	<b>4,973</b>	<b>4,022</b>	<b>1,908</b>	<b>12,852</b>	<b>10,372</b>	<b>13,421</b>
10a. Current Tax expense	1,212	1,018	527	3,247	2,543	3,512
10b. Deferred Tax expense /(reversal)	94	86	15	266	118	(3,117)
<b>11. Net Profit/ (Loss) from ordinary activities after tax</b>	<b>3,667</b>	<b>2,918</b>	<b>1,366</b>	<b>9,339</b>	<b>7,711</b>	<b>13,026</b>
12. Minority Interest	(48)	(39)	(68)	(156)	(306)	(435)
<b>13. Net Profit/ (Loss) for the period</b>	<b>3,715</b>	<b>2,957</b>	<b>1,434</b>	<b>9,495</b>	<b>8,017</b>	<b>13,461</b>
14. Paid-up Equity Share Capital(each share of Rs.2/-face value)	3,483	3,483	3,323	3,483	3,323	3,323
15. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	81,282
<b>16. Earnings per share (each share of Rs.2/-face value)</b>						
Basic EPS before and after extraordinary item (Rs.) – non-annualized	2.13	1.77	0.87	5.61	4.85	8.13
Diluted EPS before and after extraordinary item (Rs.) – non-annualized	2.13	1.77	0.87	5.61	4.85	8.13

The un-audited consolidated financial results were reviewed by the Audit Committee, and approved by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 11th February, 2016.

There are no exceptional and extraordinary items to be reported for the period under review.

The stand alone result are available on the company website [www.natcopharma.co.in](http://www.natcopharma.co.in).

Dated at Hyderabad, this, the 11th day of February, 2016.

for and on behalf of the Board of Directors,  
NATCO Pharma Limited

V.C. Nannapaneni  
Chairman & Managing Director



NATCO PHARMA LIMITED

Statement of stand-alone segment wise revenue, results and capital employed for the quarter and nine months ended on 31st December, 2015

Rs. In lakhs

PARTICULARS	THREE MONTHS ENDED (UN-AUDITED)			NINE MONTHS ENDED (UN-AUDITED)		PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	31-Dec-15	30-Sep-15	31-Dec-14	31-Dec-15	31-Dec-14	31-Mar-15
<b>01. Segment Revenue(Net)</b>						
a) Bulk Chemicals	6,773	5,198	6,339	17,551	22,297	29,468
b) Formulations	20,261	15,910	9,733	50,317	30,581	42,524
c) Job Work	149	127	176	497	612	830
d) Unallocated	132	31	788	489	1,998	2,502
<b>Total</b>	<b>27,315</b>	<b>21,266</b>	<b>17,036</b>	<b>68,854</b>	<b>55,488</b>	<b>75,324</b>
Less: Inter-Segment Revenue	2,789	1,062	340	4,719	1,516	3,767
<b>Net Sales/Income from Operations</b>	<b>24,526</b>	<b>20,204</b>	<b>16,696</b>	<b>64,135</b>	<b>53,972</b>	<b>71,557</b>
<b>02. Segment Results: Profit(+)/Loss(-) before tax and interest</b>						
a) Bulk Chemicals	433	495	732	2,062	5,450	8,043
b) Formulations	8,256	6,781	3,978	20,749	13,625	17,784
c) Job Work	137	108	144	435	505	684
d) Unallocated	43	77	587	363	681	1,354
<b>Total</b>	<b>8,869</b>	<b>7,461</b>	<b>5,441</b>	<b>23,609</b>	<b>20,261</b>	<b>27,865</b>
Less: a) Interest	332	754	811	1,863	2,146	3,013
b) Other unallocable expenditure	3,523	2,507	3,241	8,374	7,959	10,766
c) Unallocable Income	(640)	(308)	(712)	(1,231)	(1,100)	(1,355)
<b>Total Profit Before Tax</b>	<b>5,654</b>	<b>4,508</b>	<b>2,101</b>	<b>14,603</b>	<b>11,256</b>	<b>15,441</b>
<b>03. Capital Employed (Segment Assets - Segment Liabilities)</b>						
a) Bulk Chemicals	48,829	47,598	49,038	48,829	49,038	44,091
b) Formulations	50,586	47,164	38,056	50,586	38,056	44,740
c) Job Work	128	41	188	128	188	227
d) Unallocated	33,572	33,408	(3,687)	33,572	(3,687)	(1,159)
<b>Total</b>	<b>1,33,115</b>	<b>1,28,211</b>	<b>83,595</b>	<b>1,33,115</b>	<b>83,595</b>	<b>87,899</b>

The above un-audited stand-alone financial results were reviewed by the Audit Committee and approved by the Board of Directors at a meeting held on 11 February 2016 at Hyderabad. A limited review of the above stand-alone financial results was performed by the Statutory Auditors.

Equity shares of the Company with face value of Rs.10 per share were sub-divided into 5 equity shares of Rs.2 each effective 30 November 2015. Consequently, in accordance with Accounting Standard (AS) 20 - "Earnings Per Share", the basic and diluted earnings per share of the previous periods have been recomputed and disclosed accordingly.

The Company has allotted 1,600,000 equity shares of Rs.10 each at a premium of Rs.2,120.55 per equity share on 18 September 2015 pursuant to a Qualified Institutions Placement under Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 (as amended). Share issue expenses amounting to Rs.642 lakhs have been adjusted against the Securities Premium Account in terms of the provisions of Section 52 of the Companies Act, 2013.

The Board of directors have recommended an interim dividend of Rs.1.25 per equity share of Rs.2 each.

Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary.

Dated at Hyderabad, this, the 11th day of February, 2016.

for and on behalf of the Board of Directors,  
NATCO Pharma Limited

  
V.C. Nannapaneni  
Chairman & Managing Director